Previous 10 | Next 10 |
Expected to Provide Improved Gross Margins, Enhanced Patient Supply Consistency, Accelerated Inventory Production Cycle Time and Increased Control and Visibility of Commercial Product Lot Releases Additional Opportunity for Contract Manufacturing Filling Services and Capabilitie...
Jaguar Health (NASDAQ:JAGX) -21% slumps 10% on 1-for-3 reverse stock split announcement. Forward Pharma (NASDAQ:FWP) -17% after Technical Board of Appeal of the European Patent Office has dismissed Forward’s appeal of the previous decision of the EPO Opposition Division ...
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announce...
Last week, there were three significant developments with respect to ADMA. The market has taken these events to be bearish for ADMA's outlook, with the stock selling off this week. I, however, remain very bullish on ADMA. For further details see: ADMA Biologics: Recent S...
The work-at-home trend may be starting to influence corporate geography. State Street (NYSE:STT) stirred conversation during Monday's midday trading following a report that the company is planning to move out of its Manhattan offices. Intel (NASDAQ:INTC) was another big name in the news. The ...
RAMSEY, N.J. and BOCA RATON, Fla. and MARYVILLE, Tenn., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, t...
ADMA reported their Q2 earnings that revealed a 129% increase year-over-year in revenues. In addition, the company reduced their net loss, while improving gross margins. ADMA expects to pull in $100M or more in revenue during 2021 and is sticking to their plans to expand their plasma ...
Image source: The Motley Fool. ADMA Biologics Inc (NASDAQ: ADMA) Q2 2021 Earnings Call Aug 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: ADMA Biologics Inc (ADMA) Q2 2021 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q2 2021 Earnings Conference Call August 11, 2021 16:30 ET Company Participants Skyler Bloom - Director of Investor Relations & Corporate Strategy Adam Grossman - President & Chief Executive Officer Brian Lenz - Executive Vice President & Chief Financial...
Achieved Record Total Revenues of $17.8 Million in Second Quarter 2021, a 129% Increase Over Second Quarter 2020 Narrowed Gross and Net Losses Year-over-Year ADMA Now Anticipates Exiting 2021 Approaching an Annualized Revenue Run Rate of Approximately $100 Million or Mor...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 11:30:04 ET Raymond James analyst issues STRONG BUY recommendation for ADMA on May 10, 2024 09:52AM ET. The previous analyst recommendation was Strong Buy. ADMA was trading at $8.705 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...